RAAS SATELLITE SYMPOSIUM
OURO MINAS PALACE HOTEL, BELO HORIZONTE, BRAZIL,
4-5 AUGUST 2009
With the introduction of the renin inhibitor aliskiren, it is now possible to block the renin-angiotensinaldosterone system at 4 levels: renin, ACE, angiotensin II type 1 (AT1) receptors and mineralocorticoid
receptors. Not only does such blockade offer widely acknowledged beneficial effects in the vessel wall, heart
and kidney, resulting in the successful application of RAAS blockers in hypertension, heart failure, postmyocardial infarction and nephropathy, but also it has led to important new insights in the complexity of the
RAAS.
Angiotensin II metabolism results in the generation of metabolites that exert effects of their own, via newly
discovered receptors: angiotensin III, generated by aminopeptidase A and acting via angiotensin II type 2
(AT2) receptors, and angiotensin-(1-7), generated by ACE2 and acting via Mas receptors. AT2 and/or Mas
receptor stimulation is likely to underlie, at least in part, the beneficial effects of RAAS blockade. For instance,
AT2 receptor stimulation leads to bradykinin release and bradykinin type 2 (B2) receptor activation. Since this
results in the generation of both NO and endothelium-derived hyperpolarizing factors, it may well contribute to
the blood pressure-lowering effects of RAAS blockade. Not surprisingly, AT2 receptor agonists and Mas
agonists are currently being tested in animal models.
Furthermore, a (pro)renin receptor has recently been cloned which allows the ‘inactive’ precursor of renin,
prorenin, to display activity, and which may even result in angiotensin-independent signaling following
renin/prorenin binding. (Pro)renin receptor blockers might become the next class of RAAS blockers, offering
blockade of both angiotensin generation at tissue sites and (pro)renin receptor-induced, angiotensinindependent effects.
Moreover, aldosterone, in addition to its classic ‘genomic’ effects, induces rapid, non-genomic effects that are
not necessarily mediated via the mineralocorticoid receptor. Therefore, aldosterone synthase inhibitors may
yield additional effects on top of mineralocorticoid receptor blockade.
This symposium, held immediately prior to the IASH/BSH meeting (www.sbhiash2009.com.br) in Belo
Horizonte, Brazil, offers the latest insights in all the above new aspects of the RAAS. Speakers are recognized
RAAS experts from all over the world. In 4 sessions, starting with renin/prorenin, and moving via the
angiotensin-(1-7)-Mas receptor axis and the angiotensin III-AT2 receptor-bradykinin axis to the classical
angiotensin II-AT1 receptor-aldosterone pathway you will receive a full update on the RAAS. Ample time will be
available for discussion and interaction with the speakers.
Attendance of the symposium is free for those registered in the main event. However, given the limited number
of seats, we kindly request you to register beforehand using the attached registration form.
Jan Danser, Rotterdam, The Netherlands
Michael Bader, Berlin, Germany
Robson Santos, Belo Horizonte, Brazil
RAAS SATELLITE BELO HORIZONTE, BRAZIL, 4-5 AUGUST 2009
PROGRAM 4 AUGUST 2009 13.30 – 18.00 HOURS
Prorenin/renin/(P)RR/renin inhibition
Chair: Jan Danser, Rotterdam, The Netherlands & Geneviève Nguyen, Paris, France
1. Diabetes, renin system blockade and the state of the blood supply to the kidney and the eye
Norman Hollenberg, Brigham and Women's Hospital, Boston, Massachusetts, USA
2. The (pro)renin receptor: biology and roles in pathophysiology
Geneviève Nguyen, Institut National de la Santé et de la Recherche Médicale, Unit 833 and Collège de
France, Paris, France
3. Learning from handle region peptide–effective and –ineffective animal models
Atz Ichihara, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
4. Animal models with altered (pro)renin receptor expression
Michael Bader, Max-Delbrueck-Center, Berlin, Germany
ACE2-Angiotensin(1-7)-Mas axis
Chair: Mariella Gironacci, Buenos Aires, Argentina & Robson Santos, Belo Horizonte, Brazil
1. ACE2-Angiotensin(1-7)-Mas axis: an overview
Robson Santos, Department of Physiology, Federal University of Minas Gerais, Belo Horizonte, MG,
Brazil
2. Angiotensin-(1-7) and protection from hypertensive remodeling in mice
Tim L. Reudelhuber, Clinical Research Institute of Montréal (IRCM), Montréal, Canada
3. Role of ACE2 in cardio-pulmonary pathophysiology
Mohan K. Raizada, Department of Physiology and Functional Genomics, University of Florida, College
of Medicine, Gainesville, Florida, USA
4. Contrasting roles of the renin-angiotensin system in maternal uterus and fetal placenta in
normal and preeclamptic pregnancy
Bridget Brosnihan, Wake Forest Univ Health Sciences, Winston-Salem, USA
RAAS SATELLITE BELO HORIZONTE, BRAZIL, 4-5 AUGUST 2009
PROGRAM 5 AUGUST 2009 08.00 – 12.30 HOURS
Aminopeptidase A-Angiotensin III-AT2 Receptor-Bradykinin-B2 Receptor-EDHF axis
Chair: Michael Bader, Berlin, Germany & João Pesquero, São Paulo, Brazil
1. Regulation of renal sodium excretion by angiotensin III and AT2 receptors
Bob Carey, Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia
Health System, Charlottesville, VA, USA
2. Angiotensin AT2 receptor agonism – a new pharmacological concept for anti-inflammation and
tissue-protection?
Muscha Steckelings, Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Berlin,
Germany
3. Kinin receptors and obesity. A new role for kinins
João B Pesquero, Department of Biophysics, Universidade Federal de São Paulo, São Paulo, Brazil
4. Bradykinin-induced relaxation of coronary arteries: do S-nitrosothiols act as endotheliumderived hyperpolarizing factors?
A.H. Jan Danser, Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal
medicine, Erasmus MC, Rotterdam, The Netherlands
ACE-Angiotensin II-AT1 Receptor-Aldosterone-Mineralocorticoid Receptor axis
Chair: Tim Reudelhuber, Montréal, Canada & Gabriel Navar, New Orleans, USA
1. ACE and AT1 receptor function as angiotensin II-independent mechanotransducers
Jose Krieger, Heart Institute/Univ São Paulo Med School, São Paulo, Brazil
2. Structural aspects related to AT1 receptor activation
Claudio Costa-Neto, Department of Biochemistry and Immunology – Faculty of Medicine at Ribeirão
Preto – University of São Paulo, São Paulo, Brazil
3. Networking between angiotensin II and aldosterone
Rhian Touyz, Kidney Research Centre, Ottawa Health Research Institute, University of Ottawa,
Ontario, Canada
4. Effects of aldosterone on coronary function
Claude Delcayre, INSERM Unit 942 – Université Paris-Diderot, Hôpital Lariboisière, Paris, France
RAAS SATELLITE BELO HORIZONTE, BRAZIL, 4-5 AUGUST 2009
REGISTRATION FORM
Name
: ______________________________________________________________
Affiliation: ______________________________________________________________
______________________________________________________________
______________________________________________________________
E-mail: _________________________________________________________________
Attending August 4 
Attending August 5 
PLEASE SEND THIS FORM TO FAX NUMBER +31 10 7044733
OR SEND AN E-MAIL TO B.BREEMERKAMP@ERASMUSMC.NL